Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Differential Gene Regulation During Neoadjuvant Therapy Trial of EC vs DX in Breast Cancers
NCT01869192Phase 2Completed
- Sponsor
- University of Colorado Denver
- Start
- Mar 2003
- Primary completion
- Dec 2009
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of epirubicin, cyclophosphamide, docetaxel, capecitabine in breast cancer, sponsored by University of Colorado Denver. Started Mar 2003; status: completed.
02
Drugs
epirubicincyclophosphamidedocetaxelcapecitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01869192.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01869192.